2. Клинические рекомендации (проект). Остеопороз. Российская ассоциация эндокринологов и др. 2019. Режим доступа: https://rae-org.ru/system/files/documents/pdf/kr_op_24.12.2019.pdf (дата обращения – 07.04.2020).

3. https://www.sheffield.ac.uk/FRAX/tool.aspx?country=13 (date of access – 07.04.2020).

4. Camacho P.M., Petak S.M., Binkley N. et al. American Association of Clinical Endocrinologistsand American College of Endocrinology clinical practice guidelines for the diagnosis and treatmentof postmenopausal osteoporosis – 2016. Endocr Pract. 2016; 22(Suppl 4): 1–42. doi: 10.4158/EP161435.GL.

5. Kanis J., McCloskey E., Johansson H. et al. European guidance for the diagnosis and managementof osteoporosis in postmenopausal women. Osteoporosis International. 2013; 24(1): 23–57. doi:10.1007/s00198-012-2074-y.

6. Cosman F., de Beur S., LeBoff M. et al. clinician’s guide to prevention and treatment ofosteoporosis. National Osteoporosis Foundation 1150 17th St., NW, Suite 850, Washington, DC20036, Release Date: April 1, 2014.

7. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures inosteoporosisresearch. Osteoporosis Int. 2003; 14(3): 43–55.

8. Genant H., Wu C., van Kuijk C., Nevitt M. Vertebral fracture assessment using a semiquantitativetechnique. J Bone Miner Res. 2009; 8(9): 1137–48. doi: 10.1002/jbmr.5650080915.

9. Kanis J.A., on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primaryhealth-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK,2008.

10. Lesnyak O., Ershova O., Belova K. et al. Epidemiology of fracture in the Russian Federation andthe development of a FRAX model. Arch Osteoporos. 2012; 7(1–2): 67–73. doi: 10.1007/s11657-012-0082-3.

11. Алексеева Л.И., Баранова И.А., Белова К.Ю. с соавт. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Литера. 2012; 23 с.

12. http://grls.rosminzdrav.ru (дата обращения – 07.04.2020).

13. Chesnut C.H. 3rd, Skag A., Christiansen C. et al. Oral Ibandronate Osteoporosis VertebralFracture Trial in North America and Europe (BONE). Effects of oral ibandronate administereddaily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8): 1241–49.

14. Cummings S., Martin J., McClung M. et al. Denosumab for prevention of fractures inpostmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8): 756–65. doi: 10.1056/NEJMoa0809493.15. Langdahl B., Teglbjærg C., Ho P. et al. A 24-month study evaluating theefficacy and safety of denosumab for the treatment of men with low bone mineral density: resultsfrom the ADAMO trial. The Journal of Clinical Endocrinology & Metabolism. 2015; 100(4):1335–42. doi:10.1210/jc.2014-4079.

16. Orwoll E., Teglbjerg C., Langdahl B. et al. A randomized, placebo-controlled study of the effectsof denosumab for the treatment of men with low bone mineral density. The Journal of ClinicalEndocrinology & Metabolism. 2012; 97(9): 3161–69. doi:10.1210/jc.2012-1569.

17. Saag K.G., Pannacciulli N., Geusens P. et al. Denosumab vs risedronate in glucocorticoid-inducedosteoporosis: final results of a 24-month randomized, double-blind, double dummy trial. ArthritisRheumatol. 2019; 71(7): 1174–84. doi: 10.1002/art.40874.

18. Mandema J.W., Zheng J., Libanati C. Perez Ruixo J.J. Time course of bone mineral densitychanges with denosumab compared with other drugs in postmenopausal osteoporosis: a doseresponse-based meta-analysis. J Clin Endocrinol Metab. 2014; 99(10): 3746–55. doi: 10.1210/jc.2013-3795.

19. Brown J., Prince R., Deal C. et al. Comparison of the effect of denosumab and alendronate onBMD and biochemical markers of bone turnover in postmenopausal women with low bone mass:a randomized, blinded, phase 3 trial. Journal of Bone and Mineral Research. 2009; 24(1): 153–61.doi:10.1359/jbmr.0809010.

20. Choi N.K., Solomon D.H., Tsacogianis T.N. et al. Comparative safety and effectiveness ofdenosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res.2017; 32(3): 611–17. doi: 10.1002/jbmr.3019.

21. Kendler D., Roux C., Benhamou C. et al. Effects of denosumab on bone mineral density and boneturnover in postmenopausal women transitioning from alendronatetherapy. J Bone Miner Res.2009; 25(1): 72–81. doi:10.1359/jbmr.090716.

22. Tsai J., Uihlein A., Burnett-Bowie S. et al. Comparative effects of teriparatide, denosumab, andcombination therapy on peripheral compartmental bone density, microarchitecture, and estimatedstrength: the DATA-HRpQCT study. J Bone Miner Res. 2014; 30(1): 39–45. doi:10.1002/jbmr.2315.

23. Kendler D.L., Marin F., Zerbini C.A.F. et al. Effects of teriparatide and risedronate on newfractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, doubleblind, double-dummy, randomised controlled trial. Lancet. 2018; 391(10117): 230–40. doi:10.1016/S0140-6736(17)32137-2.

24. Diez-Perez A., Adachi J.D., Agnusdei D. et al.: Treatment failure in osteoporosis. OsteoporosisInt. 2012; 23: 2769–74. doi: 10.1007/s00198-012-2093-8.